More recently, the introduction of well-tolerated and highly efficacious direct acting antivirals (DAA) even among those with established HCC has allowed many more HCV-related HCC (HCV-HCC) patients to be treated, as these patients generally have advanced liver disease and comorbidities that disqualify them for interferon (IFN)-based treatment [5,6,7,8]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.